ArticleScientific reports2025
Computational investigation of natural compounds as inhibitors against macrolide-resistant protein using virtual screening, molecular docking and MD simulations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery of ERα-Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y537S Mutant Inhibition.Chemical biology & drug design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrolide resistance is the ability of bacteria to survive the effects of macrolide antibiotics, which include drugs such as erythromycin, clarithromycin, and azithromycin. Efforts to combat resistance mechanisms like this frequently involve the discovery and development of new antibiotics or therapeutic strategies capable of overcoming these modifications and restoring the efficacy of current antibiotics. In this study, we explored natural products against enzymes of macrolide resistance Macrolide 2'-phosphotransferase type I (mphA or ErmE), Macrolide 2'-phosphotransferase type II (mphB), Tripartite macrolide-specific efflux pump, Erythromycin esterase EreC, and rRNA methyltransferase (ErmAM) by molecular modelling techniques. The standard precision protocol of the Glide tool was utilized to dock a library of 1,400 natural product compounds from the LOTUS database against various enzymes associated with macrolide resistance. The docking results were assessed using the glide score, and the top ten compounds that were docked to each receptor were selected. Additionally, these selected compounds underwent ADMET analysis, suggesting their potential for therapeutic development. Among the selected compounds, LTS0271681 showed the highest binding affinity against ErmAM, LTS0263188 showed highest binding affinity against Tripartite macrolide-specific efflux pump, LTS0024216 showed the highest binding affinity against mphA, LTS0110759 showed the highest binding affinity against mphB, and LTS0100971 showed the highest binding affinity against EreC. The study incorporated molecular dynamic simulations and MM-GBSA binding free energy calculations to enhance the docking experiments. The results indicate that these compounds could potentially serve as inhibitors of macrolide resistance. However, while computational validations were part of this research, additional in-vitro studies are necessary to develop these potential inhibitors into therapeutic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.